WayPoint Biomedical Holdings, Inc. (WYPH) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerWayPoint Biomedical Holdings, Inc. (WYPH) trades at $0.0005. WayPoint Biomedical Holdings, Inc. operates in the diagnostic testing and homeland security sectors. The company develops and markets diagnostic tests and devices for health, fitness, environmental monitoring, and explosive detection. Sector: Industrials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for WYPH: WYPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
WayPoint Biomedical Holdings, Inc. (WYPH) Industrial Operations Profile
WayPoint Biomedical Holdings, Inc. focuses on developing and marketing diagnostic tests and devices for human health, fitness, and security applications. Its product portfolio includes drink spiking detection and explosive residue tests, targeting over-the-counter, point-of-care, and homeland security markets, operating within the financial services sector as a shell company.
What Is the Investment Thesis for WYPH?
WayPoint Biomedical Holdings, Inc. presents a speculative investment opportunity given its focus on niche diagnostic testing and security solutions. The company's product portfolio, including the Drink Detective and explosive detection kits, targets specific market needs. However, the company's financial performance, indicated by a negative P/E ratio of -0.25 and a market capitalization of $0.00B, suggests significant challenges. The beta of -8.36 indicates high volatility. Growth catalysts depend on successful commercialization of its diagnostic tests and expansion into the homeland security market. Investors should carefully consider the risks associated with investing in a shell company operating in the OTC market.
Based on FMP financials and quantitative analysis
WYPH Key Highlights
Market Cap of $0.00B indicates a micro-cap company with limited resources.
- P/E Ratio of -0.25 suggests the company is not currently profitable.
- Beta of -8.36 indicates high volatility compared to the market.
- Operates in the OTC market, which typically involves higher risks and lower liquidity.
- Focus on niche markets such as drink spiking detection and explosive residue testing.
Who Are WYPH's Competitors?
WYPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| LICN Lichen International Limited | $0.97 | +6.59% | — | |
| CRE Cre8 Enterprise Limited Class A Ordinary Shares | $2.65 | +1.92% | $5.40M | 62 5-pillar |
| THH TryHard Holdings Limited | $1.44 | +0.70% | $7.16M | — |
| MSGY Masonglory Limited | $4.30 | -14.17% | $7.91M | 34 5-pillar |
| PMEC Primech Holdings Ltd. | $0.54 | -1.44% | $20.8M | 35 5-pillar |
| SST System1, Inc. | $2.35 | -0.42% | $23.8M | — |
| ANPA Rich Sparkle Holdings Limited | $1.86 | -4.62% | $28.1M | — |
| NTIP Network-1 Technologies, Inc. | $1.57 | -3.68% | $35.4M | 55 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WYPH's Key Strengths?
Specialized product portfolio in niche markets.
- Proprietary diagnostic testing technology.
- Presence in over-the-counter and point-of-care markets.
- Potential for government contracts.
What Are WYPH's Weaknesses?
Limited financial resources (Market Cap: $0.00B).
- Negative P/E ratio indicating lack of profitability.
- High volatility (Beta: -8.36).
- OTC market listing increases risk.
What Are the Key Risks for WYPH?
Limited financial resources and negative profitability.
- Intense competition in the diagnostic testing market.
- Regulatory hurdles for diagnostic devices.
- OTC market listing increases risk.
- Shell company risk detected.
What Threats Does WYPH Face?
- Intense competition in the diagnostic testing market.
- Regulatory hurdles for diagnostic devices.
- Economic downturn affecting consumer spending.
- Technological obsolescence of existing products.
What Are WYPH's Competitive Advantages?
- Specialized product portfolio focusing on niche diagnostic and security applications.
- Proprietary technology in developing diagnostic tests and detection kits.
- Established presence in the over-the-counter and point-of-care markets.
- Potential for government contracts in the homeland security and defense sectors.
What Does WYPH Do?
WayPoint Biomedical Holdings, Inc. was founded in 2004 and is headquartered in Huntington Beach, California. The company operates through its subsidiary, WayPoint Biomedical, Inc., focusing on the development and marketing of diagnostic tests and devices. These products are designed for screening and monitoring human health, fitness levels, and environmental safety. A key product is the Drink Detective, a test used to detect date rape drugs such as Ketamine, GHB, and Benzodiazapines. The company also offers Health Essist tests for detecting cocaine and marijuana. Beyond health-related diagnostics, WayPoint Biomedical develops and commercializes test kits for detecting explosive devices, biowarfare/bioterrorism agents, and weapons of mass destruction. Its Frontline Explosive Test Kit is designed for detecting explosive residues. WayPoint Biomedical serves several markets, including the over-the-counter diagnostic self-testing market, the diagnostic point-of-care market, and the homeland security and defense sectors. The company's focus on specialized diagnostic solutions positions it within niche segments of the broader healthcare and security industries.
What Products and Services Does WYPH Offer?
- Develops and markets diagnostic tests for human health.
- Offers tests for detecting date rape drugs (Drink Detective).
- Provides tests for cocaine and marijuana detection (Health Essist).
- Develops test kits for detecting explosive devices.
- Creates test kits for detecting biowarfare/bioterrorism agents.
- Offers the Frontline Explosive Test Kit for explosive residue detection.
- Targets the over-the-counter diagnostic self-testing market.
- Serves the diagnostic point-of-care market.
How Does WYPH Make Money?
- Develops and manufactures diagnostic test kits and devices.
- Sells products to over-the-counter markets through retail channels.
- Markets products to point-of-care facilities such as clinics and hospitals.
- Provides solutions to homeland security and defense markets through government contracts.
What Industry Does WYPH Operate In?
WayPoint Biomedical Holdings, Inc. operates within the financial services sector as a shell company, focusing on the development and marketing of diagnostic tests and devices. The diagnostic testing market is driven by increasing health awareness and security concerns. The competitive landscape includes companies specializing in drug detection and explosive trace detection. WayPoint Biomedical's success depends on its ability to innovate and commercialize its products effectively in these competitive markets. The company's presence in the OTC market adds another layer of complexity and risk.
Who Are WYPH's Key Customers?
- Consumers seeking self-testing diagnostic solutions.
- Healthcare providers in point-of-care settings.
- Law enforcement agencies requiring drug and explosive detection tools.
- Government agencies involved in homeland security and defense.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
WayPoint Biomedical Holdings, Inc. operates in the Industrials sector. It is headquartered in Huntington Beach, US. The company is led by CEO Steven Fox. WYPH has traded publicly since 2015.
WYPH Latest News
No recent news available for WYPH.
WYPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for WYPH.
Price Targets
Wall Street price target analysis for WYPH.
WYPH MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for WYPH; grades run from A+ (80-100) to F (below 30).
Leadership: Steven Fox
CEO
Steven Fox serves as the CEO of WayPoint Biomedical Holdings, Inc. Further research is needed to determine his qualifications and expertise.
Track Record: Due to limited information, it is difficult to assess Steven Fox's track record at WayPoint Biomedical Holdings, Inc. Key achievements, strategic decisions, and company milestones under his leadership are not readily available. The company's financial performance and market capitalization suggest significant challenges during his tenure.
WYPH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that WayPoint Biomedical Holdings, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, increasing the risk associated with investing in them. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies are not subject to the same stringent listing requirements, leading to greater potential for fraud and manipulation.
- OTC Tier: OTC Other
- Limited transparency due to unknown disclosure status.
- High risk of fraud and manipulation associated with OTC Other listings.
- Low liquidity and wide bid-ask spreads.
- Potential for delisting or trading suspension.
- Shell company risk detected.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Assess the company's business plan and revenue model.
- Research the background and experience of the company's management team.
- Evaluate the company's competitive landscape and market position.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Company has been in operation since 2004.
- Focus on developing diagnostic tests and security solutions.
- Presence in the over-the-counter and point-of-care markets.
Common Questions About WYPH (Industrials)
What do analysts say about WYPH stock?
Analyst coverage of WYPH stock is limited due to its OTC listing and small market capitalization. Key valuation metrics such as P/E ratio (-0.25) suggest the company is not currently profitable.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on CEO track record.
- OTC market data may be less reliable than major exchanges.
- Shell company risk detected.